Citations

Clear

3042 citation(s) found for "Kumar, S".

Leptin Therapy Improves Metabolic Dysfunction in Immune Checkpoint Inhibitor–induced Lipodystrophy
Rad, Mona Vahidi, Saad-Omer, Suhail, Bindu, B. J., Simha, Vinaya , Vahidi Rad, Mona , Suresh Kumar Bindu, Bharath Nair

Mayo Clinic

JCEM Case Reports | December 24, 2025 | Volume: 4 | Issue: 2 | Pages: No page available

10.1210/jcemcr/luaf340 | PMID 41700130 Get It

Abstract Immune checkpoint inhibitors (ICI) have transformed cancer therapy but can induce a spectrum of endocrine complications. Acquired generalized lipodystrophy (AGL) is a rare adverse effect, leading to severe metabolic derangements including insulin-resistant diabetes, dyslipidemia, and hepatic steatosis. Marked hypoleptinemia is noted in these patients, and leptin-replacement therapy is known to be beneficial in patients with other forms of AGL. Though rare, T-cell lymphoma has been reported in patients with AGL on leptin therapy, and there has been much debate on the association between hyperleptinemia and cancer. The safety and efficacy of leptin therapy in patients with ICI-induced AGL and cancer are therefore not clear. We report a 66-year-old woman with metastatic lung adenocarcinoma who developed multiple endocrine disorders including AGL with metabolic abnormalities following pembrolizumab therapy. Initiation of daily metreleptin led to marked improvement in dyslipidemia, glycemic control, and hepatic steatosis, with no evidence of cancer recurrence after 2 years of leptin-replacement therapy. While further studies are warranted to establish the long-term efficacy and safety of leptin in ICI-induced AGL patients with a history of malignancy, this case report provides useful information for the management of these rare, challenging patients.
Body mass index and chemotherapy completion among patients with newly diagnosed ovarian cancer
Cao, Anlan , Cartmel, Brenda , Ratner, Elena , Li, Fang Yong , Schlumbrecht, Matthew , Kumar, Amanika, Crane, Tracy E. , Esserman, Denise , Irwin, Melinda L. , Ferrucci, Leah M. , Li, Fangyong , Kumar, Amanika , Crane, Tracy E. , Schlumbrecht, Matthew P , Kumar, Amanika , Esserman, Denise A

Mayo Clinic

JNCI Cancer Spectrum | December 23, 2025 | Volume: 10 | Issue: 1 | Pages: No page available

10.1093/jncics/pkaf121 | PMID 41442446 Get It

Abstract Background Several ovarian cancer studies have suggested that a body mass index (BMI) of 30 or higher is associated with lower compliance with National Comprehensive Cancer Network–recommended chemotherapy but primarily involved treatment before 2012, when dose capping was recommended for patients with higher body surface areas. Updated analyses in the contemporary treatment era are warranted. Methods In a retrospective cohort of patients with newly diagnosed ovarian cancer receiving curative-intent carboplatin plus paclitaxel in the Yale-Smilow Cancer Network (2012-2022), we evaluated BMI at diagnosis in relation to relative dose intensity (RDI)—the ratio of completed chemotherapy dose intensity to the National Comprehensive Cancer Network–recommended dose intensity—which reflects dose modification both before and during treatment. We also assessed starting RDI (which reflects modifications before treatment) and received RDI (which reflects modifications during treatment). Data on hospitalizations and hematological chemotoxicities were collected. We examined the association between BMI (<25, 25-30, ≥30) and chemotherapy completion, hospitalizations, and toxicities using multivariable linear and logistic regressions. Results Among 327 patients, the average RDI was 79.7%, and 44.3% had an RDI below 85%. Mean (SD) starting and received RDI were 97.9% (9.1%) and 81.8% (25.7%), respectively. Higher BMI was associated with higher RDI (Paggregate = .03) and received RDI (Paggregate = .04). Body mass index was not associated with starting RDI, dose reductions, delays, hospitalizations, or hematological toxicities. Conclusions Among patients with ovarian cancer treated since 2012, the overall RDI was low. Relative dose intensity was higher among patients with a BMI of 25 or higher compared with a BMI below 25. Most dose modifications occurred during treatment and not before initiation. Studies with body composition data and interventions that maximize chemotherapy completion during treatment are warranted.
The Sixth Annual Symposium of the Midwest Aging Consortium
Sturmlechner, Ines , Ashiqueali, Sarah , Martini, Hélène , Valdivieso, Karla , Franco, Ana Catarina , Guthikonda, Prashanth Kumar, Dosch, Andrew J. , Prieto, Luis I. , Asmussen, Niels C. , Latham, Amanda S. , Redden, James T, Leitschuh, Ethan A , Mashek, Douglas G. , Rodriguez-Lopez, Jhonny , Bernlohr, David , Knopf, Bailey A. , Lamming, Dudley W. , Johnston, Matthew J, Brown-Borg, Holly M., Tye, Spencer A, Rhoads, Timothy W. , Childs, Bennett G. , Li, Xinna, Jang, In Hwa, Camell, Christina D. , Miller, Zachary, Phatnani, Hemali , Haak, Andrew J. , Vanegas-Avendaño, Natalia, Akula, Ramya N, Limkar, Ajinkya R. , Leiser, Scott F, Correia, Jacinta , Bai, Hua, Olszewski, Szczepan, Seldeen, Kenneth L. , Budinger, G R Scott, Morales-Nebreda, Luisa C, Winter, Deborah R. , Spitzer, Shelly K McCrady, Rojas, Mauricio , Schafer, Marissa , Ashiqueali, Sarah A , Guthikonda, Prashanth, Rodriguez-Lopez, Jhonny , Monroe, T Blake , Bernlohr, David A , Lamming, Dudley W , Brown-Borg, Holly M , Rhoads, Timothy W , Gate, David M , Baker, Darren J , Li, Xinna , Miller, Zachary , Phatnani, Hemali , Konopka, Adam R , Limkar, Ajinkya R , Correia, Jacinta , Bai, Hua , Olszewski, Szczepan , Seldeen, Kenneth L , Morales-Nebreda, Luisa C , Winter, Deborah R , McCrady-Spitzer, Shelly K , Anderson, Rozalyn M , LeBrasseur, Nathan K , Schafer, Marissa J , Sturmlechner, Ines , Redden, James T., Passos, João F. , Robbins, Paul D. , Brown‐Borg, Holly M. , Tye, Spencer, Baker, Darren J. , Jang, In Hwa , Konopka, Adam R. , Ricke, William A. , Leiser, Scott F. , Morales‐Nebreda, Luisa , Anderson, Rozalyn M. , Mihaylova, Maria M. , Mora, Ana Lucia , LeBrasseur, Nathan K.

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | December 23, 2025 | Volume: 81 | Issue: 3 | Pages: No page available

10.1093/gerona/glaf280 | PMID 41429578 Get It

Abstract Geroscience research benefits from interdisciplinary approaches, team science, and collaborations, which collectively facilitate the discovery of aging mechanisms and their translation into tangible, clinical interventions. Since its inception in 2019, the Midwest Aging Consortium (MAC) has provided an engaging platform for aging researchers in the United States’ Midwest to connect, collaborate, and exchange ideas. The Sixth Annual Research Symposium of the MAC held at the Mayo Clinic in Rochester, Minnesota, in April 2025 highlighted the continued impact of the MAC in bringing together aging researchers, including many trainees and early career investigators, into a collaborative environment. This record-setting event featured interdisciplinary research on key aging mechanisms, including lipid metabolism, mitochondrial dysfunction, stress response, cellular senescence, and immune adaptations across organ systems. New therapeutic concepts and clinical trial approaches were presented. Cutting-edge methodologies including single-cell and spatial transcriptomics, metabolomics, and organoid cultures, to dissect aging process in tissue-specific and systemic contexts also were presented. Overall, the MAC symposium underscored the translational potential of geroscience and reinforced the MAC’s mission to accelerate aging research through regional collaborations and innovation.
IL-33 blockade attenuates vascular inflammation in a mouse model of Kawasaki disease vasculitis
Carvalho, Thacyana Teixeira de , Ross, B. Evan, Atici, Asli E. , Gomez, Angela C, Fishbein, Michael C, Aubuchon, Emily , Lee, Youngho, Lee, R., Jr, Waldiceu Verri, Chen, S. C., Crother, Timothy R. , Arditi, Moshe , Rivas, Magali Noval , Noval Rivas, Magali , Jena, Prasant Kumar , Fishbein, Michael C. , Lee, Youngho , Jacobsen, Elizabeth A. , Jr, Waldiceu Aparecido Verri

Mayo Clinic

Clinical and Experimental Immunology | December 20, 2025 | Volume: 220 | Issue: 1 | Pages: No page available

10.1093/cei/uxaf086 | PMID 41533763 Get It

Abstract The immune mechanisms underlying Kawasaki disease (KD), a febrile systemic vasculitis in children, are poorly understood. Reports indicate elevated levels of circulating IL-33 in acute KD patients; however, if IL-33 contributes to the pathogenesis of KD vasculitis remains unclear. Here, we used the Lactobacillus casei cell wall extract (LCWE)-induced murine model of KD to determine the contribution of IL-33 to vasculitis development. We observed increased expression of Il33 transcripts and IL-33 protein in LCWE-induced cardiovascular lesions. Bone marrow chimera experiments suggest that IL-33 production by both hematopoietic and stromal cells is important for LCWE-induced KD vasculitis; however, single-cell RNA sequencing, spatial transcriptomics, and flow cytometric analysis revealed that stromal cells were the predominant sources of IL-33. Furthermore, immune cells infiltrating LCWE-induced cardiovascular lesions expressed Il1rl1 transcripts, coding for the IL-33 receptor ST2. In vitro stimulation of bone marrow-derived macrophages with IL-33 enhanced their production of IL-1b and TNF-α. In vivo blockade of IL-33, using either neutralizing IL-33 antibody or Il33-/- mice, effectively attenuated LCWE-induced cardiovascular inflammation. Our results indicate that IL-33 contributes to LCWE-induced vascular inflammation through redundant mechanisms across multiple immune cell subsets rather than a single population and highlight IL-33 as a potential therapeutic target.
graphB3—an interpretable graph learning approach for predicting blood–brain barrier permeability
Kumar, Sumit , Yadav, Shashank , Vora, Dhvani Sandip , Paul, Prateek , Dhanjal, Jaspreet Kaur , Yadav, Shashank

Mayo Clinic

Briefings in Bioinformatics | December 12, 2025 | Volume: 26 | Issue: 6 | Pages: No page available

10.1093/bib/bbaf679 | PMID 41405959 Get It

Abstract Blood–Brain Barrier (BBB) is a specialized vascular structure that protects the brain by controlling what can pass from the bloodstream into the central nervous system. BBB’s highly selective nature prevents neurotoxins and foreign substances, including drugs, from entering the brain. Understanding and predicting whether a drug can cross the BBB is hence crucial in brain-related diseases. Over the past two decades, deep learning in drug discovery has witnessed an upward trend to reduce the cost, labor, and time for finding potential drugs. Majority of recent deep learning-based studies use molecular-level physiochemical properties of known drugs, which are limited and may not be sufficient to capture patterns. Here, we propose a parameter efficient Graph Convolution-based model, graphB3, which uses detailed information about the atoms in a molecule to predict the BBB permeability of drug candidates, outperforming existing methods. In addition to high predictive performance, graphB3 also offers an explanation of which parts of the molecule are most important for crossing the BBB. graphB3 can be employed to discover new BBB-permeable compounds and potential drugs. A free and easy-to-use graphB3 web server is available at https://dhanjal-lab.iiitd.edu.in/graphb3.html, and a standalone tool available at https://github.com/dhanjal-lab/graphB3.
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma
Wang, Yucai , Hwang, Steven R. , Villa, Diego , Kugathasan, Laveniya , Kumar, Anita , Joseph, Ashlee , Brooks, Taylor , Hill, Brian T. , Bond, David A. , Maddocks, Kami J. , Nizamuddin, Imran , Danilov, Alexey V. , Argao, Christine, Ruan, Jia , Khan, Nazneen B., Ouchveridze, Evguenia, Mou, Eric , Pongas, Georgios , Lossos, Izidore S. , Harris, Zoey I., Young, Philip, Greenwell, Irl Brian , Gerber, Drew G. , Wang, Michael , Narkhede, Mayur , Stack, Anthony , Messmer, Marcus , Moyo, Tamara K. , Anna, Jacob, Stanisic, Alexander , Cohen, Jonathon B. , Hwang, Steven R , Villa, Diego , Kumar, Anita , Joseph, Ashlee , Brooks, Taylor R , Bond, David A , Kahl, Brad S , Ryan, Christine E , Grover, Natalie S , Tun, Aung M , Mou, Eric , Lossos, Izidore S , Moustafa, Muhamad Alhaj , Pophali, Priyanka , Gerber, Drew , Jain, Preetesh , Wang, Michael L , Narkhede, Mayur S , Mehta, Amitkumar , Stack, Anthony C , Bhansali, Rahul S , Barta, Stefan K , Ghosh, Nilanjan , Kamdar, Manali , Stanisic, Alexander V , Karmali, Reem , Maurer, Matthew , Cerhan, James R , Cohen, Jonathon B , Wang, Yucai , Larson, Melissa C. , Kahl, Brad S. , Ryan, Christine E. , Merryman, Reid W. , Grover, Natalie S. , Ouchveridze, Evguenia, Tun, Aung M. , Ayyappan, Sabarish Ram , Muñoz, Javier , Portell, Craig A. , Baidoun, Firas , Moustafa, Muhamad Alhaj , Reagan, Patrick Michael , Banaszak, Lauren Gabriele , Pophali, Priyanka A. , Velayati, Arash , Jain, Preetesh , Mehta, Amitkumar , Bhansali, Rahul S. , Kamdar, Manali , Anna, Jacob, Karmali, Reem , Maurer, Matthew J. , Cerhan, James R. , Martin, Peter

Mayo Clinic

Blood Advances | December 11, 2025 | Volume: 10 | Issue: 4 | Pages: 1372-1380

10.1182/bloodadvances.2025018527 | PMID 41380101 Get It

Abstract The benefit of rituximab maintenance after first-line (1L) bendamustine-rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective studies. We conducted a large retrospective study at 27 US and Canadian academic centers to examine the benefit of rituximab maintenance after BR. A total of 911 patients received 1L BR between 2010 and 2020, and 703 had an objective response and no evidence of disease progression at the 3-month post-BR landmark. Among those, 394 (56%) received rituximab maintenance and 309 (44%) did not, with largely similar baseline patient and disease characteristics. In the landmark analysis, rituximab maintenance was associated with improved event-free survival (EFS; median, 49.9 vs 29.7 months; P< .001) as well as overall survival (OS; median, 109.5 vs 74.2 months; P< .001). The EFS and OS benefits were observed across most of the subgroups. EFS and OS differences were statistically significant in those who achieved a complete response to 1L BR (n = 590; median EFS, 62.7 vs 31.1 months [P< .001]; median OS, 136.1 vs 75.3 months [P< .001]), but the analysis among those who achieved a partial response to 1L BR was limited by the small sample size. These results provide additional evidence for the survival benefit of rituximab maintenance after BR in MCL and support its use in clinical trial design and routine practice.
Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma
Ohlstrom, Denis , Pilcher, William , Michaud, Marina E. , Acharya, Chaitanya R. , Satpathy, Sarthak , Gonzalez‐Kozlova, Edgar , Jayasinghe, Reyka G. , Ferguson, Katherine , Mumme, Hope , Nanda, Shivani , Mantrala, Sowmitri Karthikeya , Karagkouni, Dimitra , Pabustan, Nick , Santos, Junia Vieira Dos , Gout, Alexander M. , Kourelis, Taxiarchis , Vij, Ravi , Dhodapkar, Madhav V. , Avigan, David , Kumar, Shaji , Ding, Li , Gnjatic, Sacha , Ohlstrom, Denis J , Pilcher, William , Acharya, Chaitanya , Mumme, Hope L , Song, Yizhe , Mantrala, Sowmitri , Karagkouni, Dimitra , Schulman, Jessica , Pabustan, Nick , Vieira Dos Santos, Junia , Sherbenou, Daniel W , Keats, Jonathan J , Gout, Alexander M , Foltz, Steven , Lagana, Alessandro , Kourelis, Taxiarchis , Vij, Ravi , Dhodapkar, Madhav V , Avigan, David , Cho, Hearn Jay , Baughn, Linda B , Nooka, Ajay K , Lonial, Sagar , Kumar, Shaji K , Samur, Mehmet K , Vlachos, Ioannis S , Ding, Li , Gnjatic, Sacha , Mulligan, George , Bhasin, Manoj K , Jayasinghe, Reyka G , Song, Yizhe , Keats, Jonathan J. , Cho, Hearn Jay , Baughn, Linda B. , Nooka, Ajay K. , Lonial, Sagar , Samur, Mehmet , Vlachos, Ioannis S. , Mulligan, George

Mayo Clinic

Blood Cancer Discovery | December 9, 2025 | Volume: 7 | Issue: 2 | Pages: 266-286

10.1158/2643-3230.bcd-25-0205 | PMID 41364805 Get It

Abstract Multiple myeloma is a malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment (IME). To investigate immune correlates of treatment response and disease progression, we conducted multi-omics profiling including CD138neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138pos bulk RNA and whole-genome sequencing from 209 samples. In longitudinal analyses, interferon-γ signaling associated with markers of impaired T-cell memory after autologous stem cell transplant, whereas naïve B-cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48; P = 2.3e−4). At disease progression, multiple myeloma cells upregulated cancer–testis antigens (CTAg) and immune effector genes, with concurrent B-cell depletion, enrichment of myeloid-derived suppressor cell expression, and phenotypic T-cell exhaustion. These findings highlight dynamic immune–tumor interactions, identifying naïve B-cell reconstitution as a biomarker of durable response and CTAgs as potential targets for high-risk disease at progression. Significance: Longitudinal profiling of multiple myeloma and the IME revealed dynamic immune–tumor interactions across the disease course. Altered expression in CD8+ T cells limited memory phenotype after transplant, whereas naïve B-cell recovery associated with sustained treatment response. At progression, CTAg expression associated with immunosuppression, revealing novel mechanisms of immune dysregulation.
Accurate and Scalable Classification of Colonoscopy Neoplasia Using Machine Learning and Natural Language Processing
Broderick, Brendan T., Greenwood, Jason D. , Burger, Kelli N. , Garg, Sushil Kumar , Gurudu, Suryakanth, Ebner, Derek W. , Broderick, Brendan, Greenwood, Jason, Mahoney, Douglas, Burger, Kelli, Gurudu, Suryakanth R, Ebner, Derek , Kisiel, John, Mahoney, Douglas W. , Wallace, Michael B. , Kisiel, John B.

Mayo Clinic

Clinical and Translational Gastroenterology | December 9, 2025 | Volume: 17 | Issue: 2 | Pages: e00959

10.14309/ctg.0000000000000959 | PMID 41363713 Get It

INTRODUCTION: Colorectal cancer remains a leading cause of cancer associated death in the United States and colonoscopy the primary screening strategy for prevention. Rates of adenomatous and serrated neoplasia detection are inversely associated with postcolonoscopy colorectal cancer. This crucial quality metric depends on accurate ascertainment of colorectal neoplasia findings from both endoscopy and histopathology records. We aimed to assess the feasibility of a random forest machine learning model to rapidly and accurately categorize colorectal neoplasia from electronic health record data. METHODS: A retrospective cohort study compared neoplasia detection rates among individuals undergoing colonoscopy at a large academic institution to develop a rule-based algorithm to categorize colorectal neoplasia from endoscopy reports and pathology systematized nomenclature of medicine – clinical terms. This cohort provided a large training set to develop a natural language processing system using a random forest approach to automatically classify unstructured pathology findings into adenoma, serrated, or advanced neoplasms. This system was manually validated through an independent holdout set. RESULTS: The training set comprised 35,953 unstructured pathology reports with matched systematized nomenclature of medicine – clinical terms from 95,188 unstructured colonoscopy reports. The final model was assessed on an independent holdout set of 337 manually annotated procedures obtaining an area under the receiver operating characteristic curve of 0.997 (confidence interval [CI] 0.994–1), 0.99 (CI 0.98–1), and 0.99 (CI 0.98–0.99) for prediction of adenoma, serrated, and advanced lesions, respectively. DISCUSSION: The random forest-based hybrid natural language processing system for classification of colonoscopy results was both accurate and explainable. NLP combined with effective machine learning algorithms can provide a scalable strategy for colonoscopy quality monitoring.
Immune thrombocytopenia in patients treated with immune checkpoint inhibitors
Leaf, Rebecca Karp , Mones, Jodi V. , Shenoy, Tushar , Warsame, Mohamed , Moreira, Marina Beltrami , Panch, Sandhya , Leavitt, Andrew D., Zon, Rebecca L. , Shahamatdar, Sahar , Lim, Tristan , Cui, Can , Jiang, Debbie , Kaunfer, Sarah Allison , Durai, Lavanya , Hoge, Steven T., Dias, Julie‐Alexia , Sha, Carrie , Holmes, Aaron , Easton, Neil , Corley, Elizabeth M. , Zhao, Ethan, Li, Xingyi , Spelman, Amy, Amos, Christina Briggs, Soebbing, Doris, Shabih, Maria, Jamison, Trevor , Liu, Bolun , Hussein, Guleid , Yadav, Sumeet K. , Meara, Alexa, Juras, Patrick K. , Heskel, Marina, Reynolds, Kerry L. , Kroll, Michael H. , Leaf, David E. , Leaf, Rebecca K , Beltrami-Moreira, Marina , Cui, Can , Jiang, Debbie , Kaunfer, Sarah A , Durai, Lavanya , Dias, Julie-Alexia , Holmes, Aaron N , Easton, Neela , Corley, Elizabeth M , Liu, Bolun , Yadav, Sumeet Kumar , Elsaid, Mohamed I , Suresh, Arvind , Huang, Jennifer J , Glezerman, Ilya G , Al-Samkari, Hanny , Kroll, Michael H , Leaf, David E , Leavitt, Andrew D. , Kendall, Ellen K. , Hoge, Steven T., Li, Xingyi, Amos, Christina Briggs, Owen, Dwight H , Meara, Alexa, Go, Ronald S. , Al‐Samkari, Hanny

Mayo Clinic

Blood | December 8, 2025 | Volume: 147 | Issue: 12 | Pages: 1351-1364

10.1182/blood.2025031449 | PMID 41359796 Get It

Abstract Immune checkpoint inhibitor–associated immune thrombocytopenia (ICI-ITP) has been described in case reports and small case series, but comprehensive data on its incidence, risk factors, clinical features, treatment, and outcomes are lacking. We reviewed medical records of all adults initiating ICI therapy between 2016 and 2023 at 29 US hospitals across 7 major cancer centers to identify patients with ICI-ITP. Multivariable logistic regression was used to identify risk factors, and Cox modeling was performed to assess the association between ICI-ITP, its severity, and mortality. Among 86 467 patients, ICI-ITP occurred in 214 (0.25%). Independent risk factors included lower baseline platelet count, combination ICI therapy, stage IV cancer, and additional immune-related adverse events. ICI-ITP occurred at a median of 8 weeks (interquartile range [IQR], 4-18) after ICI initiation, with a median nadir platelet count of 41 × 109/L (IQR, 17 × 109/L to 64 × 109/L). Patients were treated with glucocorticoids (n = 106 [49.5%]), immune globulin (n = 39 [18.2%]), and thrombopoietin receptor agonists (n = 29 [13.6%]). Recovery occurred in 161 patients (75.2%) at a median of 2.3 weeks (IQR, 1.0-5.3). Of 76 patients rechallenged with ICIs, 23 (30.3%) developed recurrent ICI-ITP. ICI-ITP and its severity were associated with higher all-cause mortality, with a nearly threefold increase in risk among patients with severe ICI-ITP than those without ICI-ITP (adjusted hazard ratio, 2.96 [95% confidence interval, 2.14-4.08]). These findings establish ICI-ITP as a rare but clinically significant complication of ICI therapy, provide, to our knowledge, the first large-scale description of its risk factors and clinical course, and underscore the importance of timely recognition and management.
Liver‐Specific Biocompatible Lipid Nanoparticle‐Enabled mRNA Therapy for Haemophilia B
Arjunan, Porkizhi , Rachamala, Hari Krishnareddy, Mahalingam, Gokulnath , Murugesan, Uvarani, Rajendran, Vigneshwar, Murugesan, Mohankumar , Marepally, Srujan , Rachamala, Hari Krishnareddy, Dileepkumar, Veeragoni, Mishra, Sunil Kumar , Thangavel, Saravanabhavan , Banerjee‬‬‬‬‬‬‬‬‬, Rintu , Marepally, Srujan

Mayo Clinic

Advanced Healthcare Materials | December 8, 2025 | Volume: 15 | Issue: 9 | Pages: No page available

10.1002/adhm.202503248 | PMID 41355232 Get It

ABSTRACT The standard treatment for Haemophilia B (HB) involves frequent intravenous (IV) infusions of recombinant factor IX (FIX), which imposes a significant financial burden on patients. FIX delivery as messenger RNA using lipid nanoparticles (LNPs) presents a promising alternative, but achieving prolonged and effective protein expression remains challenging. To this end, we developed Galactosylated Lipid Nucleic Acid complex (GaLiNAx) to enhance the delivery of chemically modified FIX mRNAs. The nanocarrier encompasses an ionizable galactosylated lipid to enable receptor‐mediated endocytosis and a transfection‐competent cationic lipid for optimal mRNA complexation. We incorporated truncated albumin UTRs and base modifications in functional FIX mRNA to enhance hepatic translation. In an HB mouse model, GaLiNAx demonstrated therapeutically relevant FIX protein expression for about one month after single dose offering a cost‐effective option. Safety assessments indicated that multiple doses of GaLiNAx could be administered without toxicity to any major organs. These results highlight the potential of long‐lasting mRNA therapy as an effective protein replacement strategy for HB, paving the way for future mRNA therapeutics targeting other monogenic liver disorders.